Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovská A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Özcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG

Open source

DOI: 10.1200/jco-25-02477
Published: 2026 Feb 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-02477,
  title = {Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.},
  author = {Woyach JA and Qiu L and Grosicki S and Wrobel T and Capra M and Czyz J and Yi S and Eom KS and Panovská A and Jurczak W and Laribi K and Jacobasch L and Baker R and Agajanian R and Berkovits A and Özcan M and Lepretre S and Coombs CC and Cramer P and Lewis KL and Hill M and Bao K and Bian Y and De Batista Ribeiro SR and Bhandari NR and Ruppert AS and Leow CC and Wierda WG},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-25-02477},
  url = {https://doi.org/10.1200/jco-25-02477}
}

RIS

TY  - JOUR
TI  - Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
AU  - Woyach JA
AU  - Qiu L
AU  - Grosicki S
AU  - Wrobel T
AU  - Capra M
AU  - Czyz J
AU  - Yi S
AU  - Eom KS
AU  - Panovská A
AU  - Jurczak W
AU  - Laribi K
AU  - Jacobasch L
AU  - Baker R
AU  - Agajanian R
AU  - Berkovits A
AU  - Özcan M
AU  - Lepretre S
AU  - Coombs CC
AU  - Cramer P
AU  - Lewis KL
AU  - Hill M
AU  - Bao K
AU  - Bian Y
AU  - De Batista Ribeiro SR
AU  - Bhandari NR
AU  - Ruppert AS
AU  - Leow CC
AU  - Wierda WG
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-25-02477
UR  - https://doi.org/10.1200/jco-25-02477
ER  -

APA

JA, W., L, Q., S, G., T, W., M, C., J, C., S, Y., KS, E., A, P., W, J., K, L., L, J., R, B., R, A., A, B., M, Ö., S, L., CC, C., P, C., KL, L., M, H., K, B., Y, B., SR, D. B. R., NR, B., AS, R., CC, L., & WG, W. (2026). Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-02477

Source records

pubmed · retrieved 2026-09-26T23:24:03.981Z